| AICD | Activation-induced cell death |
| APC | Antigen presenting cell |
| BiTE | Bispecific T cell engager |
| CAIX | Carbonic anhydrase IX |
| CAR | Chimeric antigen receptor |
| CEA | Carcinoembryonic antigen |
| CTLA-4 | Cytotoxic T lymphocyte-associated antigen-4 |
| DC | Dendritic cell |
| FDA | Drug Administration (FDA) |
| FRβ | Folate receptor beta |
| HIF1-α | Hypoxia-inducible factor 1-α |
| HLA | Human leukocyte antigen |
| H2O2 | Hydrogen peroxide |
| HVEM | Herpes virus entry mediator |
| IL | Interleukin |
| IV | Intravenous |
| LAG-3 | Lymphocyte activation gene-3 |
| MCP | Macrophage chemotactic protein |
| MDSC | Myeloid-derived suppressor cell |
| MHC | Major histocompatibility complex |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MMP | Matrix metalloproteinases |
| NK | Natural killer |
| NSCLC | Non-small cell lung cancer |
| PAMP | Pathogen-associated molecular pattern |
| PD | Programmed death receptor |
| PD-L | Programmed death receptor ligand |
| PRR | Pattern recognition receptor |
| SCID | Severe combined immunodeficiency disease |
| TAM | Tumour-associated macrophage |
| TGFβ | Transforming growth factor-β |
| TIGIT | T cell immunoglobulin and ITIM domain |
| TIM-3 | T cell immunoglobulin and mucin-domain containing-3 |
| TME | Tumour microenvironment |
| Tregs | T regulatory cells |
| VEGF | Vascular endothelial growth factor |
| VISTA | V-domain Ig suppressor of T cell activation |